search
Back to results

Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas (PROMISE-P)

Primary Purpose

Prehabilitation, Pancreas Cancer, Surgery

Status
Not yet recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Preoperative optimisation program
Sponsored by
Maastricht University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Prehabilitation focused on measuring Prehabilitation, Pancreas, Preoperative optimisation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: All patients who are planned for a curative treatment with or without neoadjuvant treatment and elective pancreatic resection in one of the centres of the Dutch Pancreatic Cancer Group (i.e. all centres performing major pancreatic surgery) Exclusion Criteria: age < 18 years acute pancreatic resections (resection scheduled within two weeks)

Sites / Locations

  • Amsterdam University Medical Center
  • OLVG
  • Amphia Hospital
  • Jeroen Bosch Hospital
  • Catharina Hospital
  • Medisch Spectrum Twente
  • University Medical Center Groningen
  • Medisch Centrum Leeuwarden
  • Leiden University Medical Center
  • Maatricht University Medical Center
  • Radboud University Medical Center
  • Erasmus Medical Center
  • Maasstad Hospital
  • RAKU
  • Isala Klinieken

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Standard care

Best practice program

Arm Description

Receiving standard preoperative care

Implementation of best practice preoperative optimisation program

Outcomes

Primary Outcome Measures

Time to functional recovery
Functional recovery is achieved when all of the following five criteria are met: a) restored level of mobility at the preoperative level, b) sufficient pain control with oral medication alone, c) ability to maintain at least 50% daily required protein and energy intake, d) no intravenous fluid administration, and e) no clinical signs of infection.

Secondary Outcome Measures

Comprehensive Complication Index (CCI)
The CCI is calculated as the sum of all complications that are weighted for their severity, with a range from 0 to 100, whereby a higher score indicates presence of more complications and/or more severe complications.
Length of hospital stay
Length of hospital stay of the primary admission, measured in days
Readmissions
Readmissions within 30 days after discharge
Postoperative complications
Any postoperative complication
Incremental cost-effectiveness ratio (ICER)
The difference in costs between standard care and best practice care divided by the difference in health benefits, measured in quality-adjusted life years (QALYs).
Evaluation of health status
Reported health status measured with questionnaire EQ-5D-5L
Evaluation of quality of life for cancer patients
Reported quality of life measured with questionnaire EORTC QLQ-C30

Full Information

First Posted
April 14, 2023
Last Updated
October 18, 2023
Sponsor
Maastricht University Medical Center
Collaborators
Rising Tide Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT05851534
Brief Title
Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas
Acronym
PROMISE-P
Official Title
Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas: the Implementation of Best Practice Before Pancreatic Resection
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
February 1, 2024 (Anticipated)
Primary Completion Date
May 1, 2026 (Anticipated)
Study Completion Date
May 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Maastricht University Medical Center
Collaborators
Rising Tide Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this stepped-wedge randomized controlled trial is to investigate whether implementation of a best practice program for preoperative optimisation (prehabilitation program) with a focus on screening, assessment, and intervention of 8 potentially (partly) modifiable risk factors in patients with (suspected) pancreatic cancer will improve outcome. The main questions it will aim to answer are: Does a prehabilitation program improve the time to functional recovery after pancreatic surgery? Does a prehabilitation program lead to a reduction in the Comprehensive Complication Index after pancreatic surgery?
Detailed Description
Background In the past, little attention has been given in the daily practice to the patient's condition before an operation. Recent studies have shown the benefit of preoperative optimisation programs. However, these studies consisted only of smaller studies and were mainly performed in patients who underwent colorectal surgery. Although promising, unfortunately, strong evidence to support the contribution of prehabilitation to optimize the functional outcome after surgery is still lacking and consequently it is not included in the Dutch basic health insurance package. Objective To investigate whether implementation of a best practice program for preoperative optimisation of patients with a focus on screening, assessment, and intervention of 8 potentially (partly) modifiable risk factors (low (aerobic) fitness level, malnutrition, low psychological resilience, comorbidities (iron deficiency (anaemia), impaired glucose control and frailty), and intoxications (alcohol and smoking behaviour)) will improve the time to functional recovery. Study design A nationwide stepped-wedge cluster randomized trial. In this design all participating centres will cross over from current practice to the best practice program, in a randomised order. At the end of the study, all centres will have implemented the best practice program. Study population All 15 centres performing major pancreatic surgery in the Netherlands collaborating within the Dutch Pancreatic Cancer Group (DPCG). Intervention Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed. This program is based on findings in previous screening and prehabilitation programs, a national inventory of current preoperative care protocols and expert opinion. Consensus upon this program was reached with pancreatic surgeons from all centres of the DPCG. The final program was critically reviewed by the advisory committee of internationally respected experts in the field of prehabilitation and pancreatology. Comparison Preoperative care according to current practice.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prehabilitation, Pancreas Cancer, Surgery, Postoperative Complications
Keywords
Prehabilitation, Pancreas, Preoperative optimisation

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Stepped-wedge cluster randomized superiority trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2011 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard care
Arm Type
No Intervention
Arm Description
Receiving standard preoperative care
Arm Title
Best practice program
Arm Type
Experimental
Arm Description
Implementation of best practice preoperative optimisation program
Intervention Type
Behavioral
Intervention Name(s)
Preoperative optimisation program
Intervention Description
Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed
Primary Outcome Measure Information:
Title
Time to functional recovery
Description
Functional recovery is achieved when all of the following five criteria are met: a) restored level of mobility at the preoperative level, b) sufficient pain control with oral medication alone, c) ability to maintain at least 50% daily required protein and energy intake, d) no intravenous fluid administration, and e) no clinical signs of infection.
Time Frame
On average 6-10 days
Secondary Outcome Measure Information:
Title
Comprehensive Complication Index (CCI)
Description
The CCI is calculated as the sum of all complications that are weighted for their severity, with a range from 0 to 100, whereby a higher score indicates presence of more complications and/or more severe complications.
Time Frame
30 days postoperative
Title
Length of hospital stay
Description
Length of hospital stay of the primary admission, measured in days
Time Frame
On average 2 weeks postoperative
Title
Readmissions
Description
Readmissions within 30 days after discharge
Time Frame
30 days after discharge of primary admission
Title
Postoperative complications
Description
Any postoperative complication
Time Frame
During primary admission, on average 14 weeks postoperative
Title
Incremental cost-effectiveness ratio (ICER)
Description
The difference in costs between standard care and best practice care divided by the difference in health benefits, measured in quality-adjusted life years (QALYs).
Time Frame
1 year postoperative
Title
Evaluation of health status
Description
Reported health status measured with questionnaire EQ-5D-5L
Time Frame
At baseline, 3 months and 12 months postoperative
Title
Evaluation of quality of life for cancer patients
Description
Reported quality of life measured with questionnaire EORTC QLQ-C30
Time Frame
At baseline, 3 months and 12 months postoperative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients who are planned for a curative treatment with or without neoadjuvant treatment and elective pancreatic resection in one of the centres of the Dutch Pancreatic Cancer Group (i.e. all centres performing major pancreatic surgery) Exclusion Criteria: age < 18 years acute pancreatic resections (resection scheduled within two weeks)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marcel den Dulk, MD PhD
Phone
+3143 3875492
Email
marcel.den.dulk@mumc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Heleen Driessens, MD
Phone
+316 83058108
Email
h.driessens@umcg.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marcel den Dulk, MD PhD
Organizational Affiliation
Maastricht University Medical Center/ University Maastricht
Official's Role
Principal Investigator
Facility Information:
Facility Name
Amsterdam University Medical Center
City
Amsterdam
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marc Besselink, MD PhD
Facility Name
OLVG
City
Amsterdam
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sebastiaan Festen, MD PhD
Facility Name
Amphia Hospital
City
Breda
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Schreinemakers, MD PhD
Facility Name
Jeroen Bosch Hospital
City
Den Bosch
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Koop Bosscha, MD PhD
Facility Name
Catharina Hospital
City
Eindhoven
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ignace de Hingh, MD PhD
Facility Name
Medisch Spectrum Twente
City
Enschede
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daan Lips, MD PhD
Facility Name
University Medical Center Groningen
City
Groningen
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joost Klaase, MD PhD
Facility Name
Medisch Centrum Leeuwarden
City
Leeuwarden
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eric Manusama, MD PhD
Facility Name
Leiden University Medical Center
City
Leiden
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sven Mieog, MD PhD
Facility Name
Maatricht University Medical Center
City
Maastricht
ZIP/Postal Code
6202AZ
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marcel den Dulk, MD PhD
Facility Name
Radboud University Medical Center
City
Nijmegen
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kees van Laarhoven, MD PhD
Facility Name
Erasmus Medical Center
City
Rotterdam
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Casper van Eijck, MD PhD
Facility Name
Maasstad Hospital
City
Rotterdam
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Edwin van der Harst, MD PhD
Facility Name
RAKU
City
Utrecht
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hjalmar van Santvoort, MD PhD
Facility Name
Isala Klinieken
City
Zwolle
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vincent Nieuwenhuijs, MD PhD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All of the individual participant data collected during the trial will be shared, after deidentification upon reasonable request.
IPD Sharing Time Frame
Beginning 3 months and ending 5 years following article publication
IPD Sharing Access Criteria
Data will be available upon request. Request should be directed to marcel.den.dulk@mumc.nl.

Learn more about this trial

Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas

We'll reach out to this number within 24 hrs